These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 16005054)

  • 1. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
    Brustmann H
    Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
    Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
    J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
    Brustmann H
    Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study.
    Brustmann H
    Gynecol Oncol; 2004 Jan; 92(1):268-76. PubMed ID: 14751170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.
    Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA
    Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR.
    Poremba C; Heine B; Diallo R; Heinecke A; Wai D; Schaefer KL; Braun Y; Schuck A; Lanvers C; Bànkfalvi A; Kneif S; Torhorst J; Zuber M; Köchli OR; Mross F; Dieterich H; Sauter G; Stein H; Fogt F; Boecker W
    J Pathol; 2002 Oct; 198(2):181-9. PubMed ID: 12237877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear hTERT immunohistochemical expression is associated with survival of patients with urothelial bladder cancer.
    Mavrommatis J; Mylona E; Gakiopoulou H; Stravodimos C; Zervas A; Giannopoulos A; Nakopoulou L
    Anticancer Res; 2005; 25(4):3109-16. PubMed ID: 16080574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
    Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas.
    Tanner B; Grimme S; Schiffer I; Heimerdinger C; Schmidt M; Dutkowski P; Neubert S; Oesch F; Franzen A; Kölbl H; Fritz G; Kaina B; Hengstler JG
    Gynecol Oncol; 2004 Feb; 92(2):568-77. PubMed ID: 14766249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
    Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
    Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.